Jag Singh M.D.
AUTHOR

Jag Singh M.D.

Tap the gear icon above to manage new release emails.
Jag Singh is a Professor of Medicine at Harvard Medical School. He is the former Clinical Director of the Cardiology Division and the Roman W. DeSanctis Endowed Chair in Cardiology at Mass General Hospital. He is also the Founding Director of the Resynchronization and Advanced Cardiac Therapeutics Program, at the Massachusetts General Hospital Heart Center.
Jag grew up in India and did his early medical training in Pune and Bombay. He received his medical degree from Pune University, India and completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Mass General Hospital. He also earned a doctorate from Oxford University, a Master of science in clinical investigation from MIT-Harvard and a research fellowship at the Framingham Heart Study.
Dr. Singh has over 400 peer reviewed publications and has given over 500 invited lectures at national and international conferences. He is the former Deputy Editor of the Journal of American College of Cardiology: Clinical EP and Editor-in-chief of the Current Treatment Options in Cardiovascular Medicine.
Dr. Singh is the national & global principal investigator on several ongoing multi-center clinical trials in device therapy, sensor strategies and artificial intelligence for heart failure and atrial fibrillation. Much of his current efforts are focused on healthcare redesign, digital health, and medical device innovations.

Learn more at www.jagsinghmd.com
Read more Read less

Try Audible membership today. Start enjoying the benefits.

Try Audible for free with an audiobook of your choice.
Auto-renews at AUD $8.99/mo after 30 days. Cancel anytime.

Most Popular

Product list
  • Preview
    • Sensors, Artificial Intelligence, and the Reinvention of Medicine
    • By: Dr. Jag Singh
    • Narrated by: Mike Chamberlain
    • Length: 11 hrs and 41 mins
    • Release date: 04-08-2023
    • Language: English
    • Not rated yet

    $27.31 or free with 30-day trial